Publication
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.
Ryan C Lynch, Christina Poh, Mazyar Shadman, Brian G Till, Mengyang Di, Chaitra S Ujjani, Vikram Raghunathan, Stephen D Smith, David Maloney, Daria Gausman, Heather Rasmussen, David A Russler-Germain, Todd A Fehniger, David M Kurtz, Ash Alizadeh, Jenna Voutsinas, Ajay K Gopal
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: Chemoimmunotherapy has been the standard approach for untreated indolent B-cell lymphoma. We hypothesized that initial use of the CD3/CD20 bispecific mosunetuzumab followed by response-adapted polatuzumab vedotin and obinutuzumab would yield an optimized chemotherapy-free…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT05169658registry_reference1.00
Candidate 1
- cancerNon-Hodgkin Lymphomadictionary0.60
Registered trialsNCT05169658
Curated evidence
Evidence citing this paper (0)
Data not yet available